Effects of fibers and gut microbiota on low-grade inflammatory human disease
Viewpoint

Effects of fibers and gut microbiota on low-grade inflammatory human disease

Cinzia Parolini

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy

Correspondence to: Cinzia Parolini. Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, via Balzaretti, 9 – 20133 Milan, Italy. Email: cinzia.parolini@unimi.it.

Comment on: Wen W, Schwabe RF. Soluble Fibers Improve Metabolic Syndrome but May Cause Liver Disease and Hepatocellular Carcinoma. Hepatology 2019;70:739-41.


Submitted Jun 29, 2019. Accepted for publication Jul 25, 2019.

doi: 10.21037/hbsn.2019.07.15


Obesity represents a major public health problem, as it leads to metabolic disorders involved in the development of type 2 diabetes, fatty liver diseases, cardiovascular diseases and cancer (1). The Western lifestyle, including over-feeding of highly refined diets and sedentary behavior, is associated with systemic low-grade inflammation, responsible for chronic degenerative disease. Moreover, animal and human data have demonstrated the impact of high-fat diet feeding on the onset of metabolic endotoxemia. This latter, being characterized by increase blood lipopolysaccharide (LPS) levels, triggers low-grade inflammation and contributes to the development of obesity. The gut microbiota are a candidate sources of plasma LPS. Indeed, LPS is a major component of the outer membrane in Gram-negative bacteria and its plasma levels are correlated with changes in intestinal microbiota where the Gram-negative to Gram-positive ratio is increased by high fat feeding (1). Not surprising that in humans, obesity is characterized by dysbiosis, i.e. imbalances in the composition and function of the intestinal microbes. Currently, many studies are being conducted to assess the contribution of intestinal microflora metabolites [mainly short-chain fatty acids (SCFAs)] to the organism’s homeostasis. Dietary fibers have been promoted for their health benefits and high-fiber intake has been reported as beneficial in numerous chronic diseases (2). However, we have to keep in mind that consumption of dietary fiber significantly alters the composition of the gut microbiota. For instance, addition of fibers to the diet increases the abundance of butyrate-producing bacteria Roseburia species and Eubacterium rectale, whereas a low-fiber diet is associated to a major decrease in this group, with Faecalibacterium prausnitzii becoming the main butyrate-producer. Hence, a greater understanding of the interaction between dietary fibers and the intestinal microbiota could represent a mean of maintaining or improving the community of gut microorganisms, particularly when dysbiosis exists. In addition, although various data indicate that increased SCFAs production positively affects the host by exerting antiobesity and antidiabetic effects, some in vitro and in vivo studies have indicated that overproduction or accumulation of SCFAs in the bowel may lead to obesity and cancer development, owing to increased energy accumulation and elevation of the inflammatory state. As correctly pointed out in the recent paper by Wen and Schwabe, more experimental and epidemiologic data are needed to completely elucidate the link among dietary fibers, gut microbiota and the onset of low-grade inflammatory diseases (3). However, the authors commented about the recent study by Singh et al. (4) and based only on these results stated that soluble fibers could be associated to liver disease and hepatocellular carcinoma. Specifically, it will be a great achievement to shed light on the influence that SCFAs exert on the intestinal environment as well as on distal tissues and organs. SCFAs, mainly acetate, propionate and butyrate, are organic acid produced by intestinal microbial fermentation of dietary fibers. Various mechanisms have been highlighted to justify the biological effects of butyrate: (I) inhibition of histone deacetylase (HDAC); (II) downregulation of neuropilin-1 (NRP-1); (III) activation of G-protein-coupled receptors, GPR41, GPR43 and GPR109A, and of the peroxisome proliferator-activated receptor γ (PPARγ); (IV) modulation of canonical Wnt signaling pathway; (V) activation of AIM2 and NLRP3 inflammasomes, enhancing production of interleukin-18 (IL-18) and epithelial barrier function; (VI) differentiation of T lymphocytes into effector (Te) and regulatory (T reg) T cells; and (VII) modulation of T lymphocytes and dendritic cell functions (5). In the meantime, SCFAs can reach the liver through the portal vein and directly promote hepatic triglyceride accumulation and gluconeogenesis. In addition, various data have demonstrated that butyrate appears to have “paradoxical” effects on colonic epithelial proliferation due to the fact that the response of proliferative cells to butyrate are affected by the dose of butyrate, the physiological conditions under which the study was performed and the phenotype of the target cells (3). Butyrate can instead suppress proliferation in hyperproliferation situations (i.e., colon cancers cells), or stimulate proliferation in impaired energy status (i.e., atrophic colon) or having no effect in normal tissues. Similarly, butyrate can promote or inhibit apoptosis (1).

The concept of prebiotics is based on the possibility of favorable modulating the gut microbiota composition to maintain and/or promote health, using nutrients such as non-digestible, fermentable carbohydrates. Among these, the prebiotic effect of inulin-type fructans (ITF) and fructo-oligosaccharires (GOS) has been extensively studied in vivo, showing a selective stimulation of Bifidobacteria and Lactobacilli growth. Moreover, in 4 out of 13 randomized controlled trials dietary IFT was positively associated to decrease in serum glucose and fasting insulin concentrations. These effects were a consequence of the ability of IFT to increase the number of endocrine L cells in the jejunum and colon, enhancing the production and secretion of glucagon-like peptide-1 (GLP-1) and reducing glycemia. However, a recent meta-analysis of randomized controlled trials has shown that modulation of the gut microbiota via prebiotic supplementation may present modest effects on body weight and waist circumference in obese subjects. Conflicting results have been also obtained from cohort-based epidemiological studies that aimed at finding a link between fiber intake and colorectal cancer prevention (6). On the other hand, Donohoe et al using a mouse model demonstrated that dietary fiber could protect against colorectal cancer in a microbiota- and butyrate-dependent manner (7). In line with these data are the results published in a recent paper where butyrate was able to significantly abolish the neointimal formation in partially ligated carotid arteries of mice throughout NLRP3 inflammasome activation (8).

In conclusion, numerous studied have elucidated the complexity of the mechanisms responsible for the effects of SCFAs, mainly butyrate. However, more mechanistic and clinical studies to entirely clarify the role of dietary fibers on human health are needed.


Acknowledgments

None.


Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


References

  1. Parolini C. Effects of Fish n-3 PUFAs on Intestinal Microbiota and Immune System. Mar Drugs 2019;17. [Crossref] [PubMed]
  2. Parolini C, Manzini S, Busnelli M, et al. Effect of the combinations between pea proteins and soluble fibres on cholesterolaemia and cholesterol metabolism in rats. Br J Nutr 2013;110:1394-401. [Crossref] [PubMed]
  3. Wen W, Schwabe RF. Soluble Fibers Improve Metabolic Syndrome but May Cause Liver Disease and Hepatocellular Carcinoma. Hepatology 2019;70:739-41. [PubMed]
  4. Singh V, Yeoh BS, Chassaing B, et al. Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. Cell 2018;175:679-94.e22. [Crossref] [PubMed]
  5. Ratajczak W, Rył A, Mizerski A, et al. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol 2019;66:1-12. [PubMed]
  6. Pan P, Yu J, Wang LS. Colon Cancer: What We Eat. Surg Oncol Clin N Am 2018;27:243-67. [Crossref] [PubMed]
  7. Donohoe DR, Holley D, Collins LB, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov 2014;4:1387-97. [Crossref] [PubMed]
  8. Yuan X, Wang L, Bhat OM, et al. Differential effects of short chain fatty acids on endothelial Nlrp3 inflammasome activation and neointima formation: Antioxidant action of butyrate. Redox Biol 2018;16:21-31. [Crossref] [PubMed]
Cite this article as: Parolini C. Effects of fibers and gut microbiota on low-grade inflammatory human disease. Hepatobiliary Surg Nutr 2019;8(6):664-665. doi: 10.21037/hbsn.2019.07.15